1 / 13

Cancer Care Engineering Colorectal Cancer Gabriela Chiorean, M.D.

Cancer Care Engineering Colorectal Cancer Gabriela Chiorean, M.D. June 26, 2009. Rationale in colorectal cancer. Perform OMICs of healthy, polyps, cancer Compare OMICs between cancer, polyps and healthy: develop new screening and risk assessment tools

raoul
Download Presentation

Cancer Care Engineering Colorectal Cancer Gabriela Chiorean, M.D.

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Cancer Care Engineering Colorectal CancerGabriela Chiorean, M.D. June 26, 2009

  2. Rationale in colorectal cancer • Perform OMICs of healthy, polyps, cancer • Compare OMICs between cancer, polyps and healthy: develop new screening and risk assessment tools • Analyse changes in OMICs with treatment and correlate with response/toxicity: predictive markers • Mathematical modeling and bio-mapping • Cancer care delivery

  3. Rationale: CCE now GENOMICS METABOLOMICS GLYCO- PROTEOMICS LIPIDOMICS C R C BIOMAP Mathematical modeling

  4. Schema IUCRO-0221CCE in CRC active April 2009 S A M P L E S Blood (Serum) 7 mL red top Metab, vit D S H I P D R Y I C E • N=270 • Stratification: • Healthy (n=90) • Polyps (n=90) • Cancer (n=90) • stg 1/2 • stg 3 • stg 4 metastatic Blood (Plasma) 21 mL purple top Genomics, lipidomics, glycoproteomics Tissue 10 mg polyp or 50 mg cancer / 50 mg normal tissue 8-hr fasting

  5. N= 5 Samples CollectionHealthy Controls Sign ICS (RN) Label specimens Healthy if no polyps/tumor Screening Colonoscopy – GI Clinic Collect by RN/processing CRS Blood 1x 7 mL glass red top 3 x 7 mL plastic lavender Questionnaires diet/environmental exposures

  6. N= 3 Samples CollectionAdenomatous Polyps Sign ICS (RN) Polyps identified Label specimens Polyp Screening Colonoscopy – GI Clinic Collect by RN/processing CRS Blood 1x 7 mL glass red top 3 x 7 mL plastic lavender Tissue procurement/Research specialist -Polyp cut in ½ -Place in tube with no preservative -Freeze at -70oC Questionnaires diet/environmental exposures

  7. Samples CollectionCancer N= 8 Call tissue procurement -Tumor tissue ~ 50 mg -Normal mucosa ~ 50 mg -Place in tube with no preservative -Freeze at -70oC Sign ICS (RN) Chemotherapy Follow-up Surgery Collect by RN/processing tissue procurement Blood: 1 x 7 mL red top glass tube 3 x 7 mL lavender plastic tubes Questionnaires: diet/environmental exposures Every 3 months Up to 24 months

  8. CCE Blood Acquisition Protocols Glass Red Top Tube (1) Volume = 7mL Glass Purple Top Tubes (EDTA) (3) Volume = 7mL /tube Following blooddraw, patients and care givers administered diet and life style questionnaire Page: Amber Allen (page #) for transport to laboratory (RT) and processing 0.2 mL (2) Whole Blood into freezing tubes containing comet assay solution, mix, place on dry ice, FREEZE (-80oC) Maximum time at RT from draw to centrifugation: 45-60 min. Centrifuge: 1500g, RT, 15 min Maximum time at RT from draw to Whole Blood Removal: 20 min. Remaining whole blood Serum ( ~ 3mL), place on wet ice Maximum time at RT from draw to centrifuge: 30 min. Centrifuge: 1750g, RT, 15 min REGULAR EPPENDORF TUBES 0.3 mL (2) FREEZE (-80 oC) Metabolomics NMR 0.2 mL (2) FREEZE (-80 oC) Metabolomics MS 0.5 mL (2) FREEZE (-80 oC) Vitamin D Analysis Plasma (~ 6mL), place on wet ice Pellets (2); resuspend (1), combine with second pellet, re-centrifuge 1750g RT 5 min, decant, place on dry ice: FREEZE (-80 oC) SNP SILICONIZED EPPENDORFTUBES 0.2 mL (2) FREEZE (-80 oC) Lipidomics REGULAR EPPENDORF TUBES 1.5 mL (1) FREEZE (-80 oC)Glycoproteomics 0.2 mL (1) FREEZE (-80 oC) Proteomics 1.5 mL (1) LONG TERM STORAGE (LIQUID N2); Regular Eppendorf Tubes 0.2 mL (12) LONG TERM STORAGE (LIQUID N2); Siliconized Eppendorf Tubes 0.5 mL (2) LONG TERM STORAGE (LIQUID N2)

  9. Metabolomics Typical 2D GCxGC/MS data from a colon cancer patient serum sample. After derivitization, approximately 800 metabolites are observed (many of the lower intensity peaks are not evident in this figure). Dan Raftery-Purdue

  10. Metabolomics Combination of the GC PCA data with NMR PCA data improves the classification to 95%. In the figure, 2 PCs from the GCxGC/TOF dataset are combined with 1 PC from the NMR data. Oblong shapes are used to indicate 95% confidence limits.

  11. Schema IUCRO-0198Metabolomics in CRC S A M P L E S Blood (Serum) 7 mL red top S H I P D R Y I C E • N=150 • Stratification: • Healthy (n=30) • Polyps (n=30) • Cancer (n=90) • stg 1/2 • stg 3 • stg 4 metastatic Urine 10 mL Tissue 10 mg polyp or 50 mg cancer / 50 mg normal tissue 8-hr fasting

  12. Principle Component Analysis of Metabolites in serum in IUCRO-0198 Dan Raftery, Lingyan Liu - Purdue

  13. Investigators: Indiana University Gabriela Chiorean - Oncology Pat Loehrer – Oncology Stephen Williams - Oncology Yan Xu - Lipidomics Jim Klaunig - Genomics Bruce Robb - Surgery Eric Wiebke - Surgery Doug Rex - GI Mike Chiorean - GI Charles Kahi - GI Peter Johnstone – Rad Onc Oscar Cummings - Pathology Purdue University Marietta Harrison - Chemistry Daniel Raftery – Metabolomics Fred Regnier – Proteomics - Glycoproteomics Dorothy Teegarden – Vitamin D Min Zhang – Statistical Modeling Jake Chen – Biological Modeling

More Related